QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.107.035055v1 72/1/18    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ji, C. Articles by Sankuratri, S. Search for Related Content PubMed PubMed Citation Articles by Ji, C. Articles by Sankuratri, S.

CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor

Department of Viral Diseases (C.J., J.Z., M.D., E.R., A.D., N.C., S.S.) and Genome Informatics (S.C.), Roche Palo Alto, Palo Alto, California; and Pharmaceuticals Division, Roche Penzberg, Penzberg, Germany (M.B.)

A panel of four CCR5 monoclonal antibodies (mAbs) recognizing different epitopes on CCR5 was examined in CCR5-mediated cell-cell fusion assay, alone or in combination with a variety of small molecule CCR5 antagonists. Although no antagonism was observed between any of the CCR5 inhibitors, surprisingly potent synergy was observed between CCR5 mAbs and antagonists, and the synergistic activity was confirmed in other antiviral assays. Strong synergy was also observed between CCR5 inhibitors and the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide. There was no synergy observed between small molecule CCR5 inhibitors; however, potent synergy was observed between mAbs recognizing different parts of CCR5. In all synergistic combinations, greater synergy was achieved at higher percent inhibition levels. A negative correlation was found between the degree of synergy between the two classes of CCR5 inhibitors and the ability to compete each other for binding to the receptor. For example, the greatest synergy, observed between the mAb ROAb13 and the small molecule inhibitor maraviroc, did not interfere with binding to CCR5 for either inhibitor, whereas no synergy was found between mAb 45523 and maraviroc, which do compete for binding to CCR5. In addition, in contrast to a recent report, the CCR5 inhibitors tested here were found to inhibit the same stage of HIV entry. Based on the data presented here, we hypothesize that CCR5 inhibitors exert synergistic antiviral actions through a cobinding mechanism.

Address correspondence to: Changhua Ji, Department of Viral Diseases, Roche Palo Alto, 3431 Hillview Ave., Palo Alto, CA 94304. E-mail: changhua.ji{at}roche.com

This article has been cited by other articles:

				M. F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.-R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1604 - 1612. [Abstract] [Full Text] [PDF]